TAURX THERAPEUTICS LTD.
- Country
- πΈπ¬Singapore
- Ownership
- Private
- Established
- 2002-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://taurx.com
Clinical Trials
50
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (42 trials with phase data)β’ Click on a phase to view related trials
TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease
- Conditions
- Alzheimer Disease
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- TauRx Therapeutics Ltd
- Registration Number
- NCT03539380
Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment
- Conditions
- Alzheimer Disease
- Interventions
- Drug: PlaceboDrug: TRx0237 16 mg/dayDrug: TRx0237 8 mg/dayDrug: Control
- First Posted Date
- 2018-02-26
- Last Posted Date
- 2025-09-04
- Lead Sponsor
- TauRx Therapeutics Ltd
- Target Recruit Count
- 598
- Registration Number
- NCT03446001
- Locations
- πΊπΈ
Xenoscience, Phoenix, Arizona, United States
πΊπΈArizona Research Center, Phoenix, Arizona, United States
πΊπΈImaging Endpoints Research, Scottsdale, Arizona, United States
Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
- Conditions
- Behavioral Variant Frontotemporal DementiaAlzheimer's Disease
- Interventions
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- TauRx Therapeutics Ltd
- Target Recruit Count
- 913
- Registration Number
- NCT02245568
- Locations
- πΊπΈ
Xenoscience, Inc / 21st Century Neurology, Phoenix, Arizona, United States
πΊπΈSouthern California Research, LLC, Fountain Valley, California, United States
πΊπΈFeldman, Robert MD, Laguna Hills, California, United States
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: TRx0237 200 mg/dayDrug: Placebo
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2018-03-14
- Lead Sponsor
- TauRx Therapeutics Ltd
- Target Recruit Count
- 800
- Registration Number
- NCT01689233
- Locations
- πΊπΈ
Xenoscience, Inc / 21st Century Neurology, Phoenix, Arizona, United States
πΊπΈNoesisPharma Clinical Trials, Phoenix, Arizona, United States
πΊπΈCITrials, Bellflower, California, United States
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: TRx0237 250 mg/dayDrug: TRx0237 150 mg/dayDrug: Placebo
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2018-03-14
- Lead Sponsor
- TauRx Therapeutics Ltd
- Target Recruit Count
- 891
- Registration Number
- NCT01689246
- Locations
- πΊπΈ
Xenoscience, Inc/ 21st Century Neurology, Phoenix, Arizona, United States
πΊπΈFeldman, Robert MD, Laguna Hills, California, United States
πΊπΈUniversity of Southern California, Los Angeles, California, United States
- Prev
- 1
- 2
- 3
- Next